Literature DB >> 20332764

Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells.

N Yu Lukyanova1.   

Abstract

AIM: To study the influence of homocysteine on the mechanisms of drug resistance formation.
METHODS: In current study human MCF-7 breast cancer cells and A2780 ovarian cancer cells sensitive to anticancer drugs were used. To access the viability of cells, we applied 3-[4,5-dimethylthiazol-2-1]-2,5-diphenyltetrazolium bromide colorimetric assay (MTT-test). Expression of Bcl-2, p-glycoprotein (P-gp), glutathione S-transferase (GST) and E-cadherin was studied by immunocytochemistry.
RESULTS: A2780 and MCF-7 cells were treated by homocysteine. It was shown that every next treatment with homocysteine (up to 5th) decreased the sensitivity of A2780 and MCF-7 cells to cytotoxic drugs. Immunocytochemical study of molecular profile of A2780 and MCF-7 cells after long-term cultivation with homocysteine has been carried out and has revealed that such treatment resulted in the induction of Bcl-2, P-gp, GST and E-cadherin expression. This indicates that incubation of studied cells with homocysteine leads to simultaneous induction of expression of drug resistance markers to cisplatin and doxorubicin.
CONCLUSION: Cultivation of MCF-7 and A2780 cells with homocysteine leads to simultaneous development of resistance to doxorubicine and cisplatin. The development of drug resistance is diverse for different drugs and varies among cell lines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332764

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  6 in total

1.  Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro.

Authors:  Yang Shen; Mulan Ren; Yuehua Shi; Yunxia Zhang; Yunlang Cai
Journal:  Exp Ther Med       Date:  2011-08-11       Impact factor: 2.447

2.  The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.

Authors:  Magdalena Kedzierska; Joanna Malinowska; Rafal Glowacki; Beata Olas; Edward Bald; Arkadiusz Jeziorski; Janusz Piekarski
Journal:  Mol Cell Biochem       Date:  2011-05-01       Impact factor: 3.396

Review 3.  Platinum resistance in breast and ovarian cancer cell lines.

Authors:  Niels Eckstein
Journal:  J Exp Clin Cancer Res       Date:  2011-10-04

4.  Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.

Authors:  Wen-Jing Zhu; Shu-di Yang; Chen-Xi Qu; Qiao-Ling Zhu; Wei-Liang Chen; Fang Li; Zhi-Qiang Yuan; Yang Liu; Ben-Gang You; Xue-Nong Zhang
Journal:  Int J Nanomedicine       Date:  2017-04-26

5.  Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.

Authors:  Xi Chen; Xiao-Yu Zhang; Yang Shen; Li-Li Fan; Mu-Lan Ren; Yong-Ping Wu
Journal:  Oncotarget       Date:  2016-12-13

6.  Cajanol Sensitizes A2780/Taxol Cells to Paclitaxel by Inhibiting the PI3K/Akt/NF-κB Signaling Pathway.

Authors:  Ming Sui; Hairong Yang; Mingqi Guo; Wenle Li; Zheng Gong; Jing Jiang; Peiling Li
Journal:  Front Pharmacol       Date:  2021-12-08       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.